We are pleased to announce that we have joined the @MabDesign_fr network! 🌟 We look forward to this new collaboration as we continue to grow and partner within the #French biotech sector.
To learn more about our services, visit https://t.co/CdWadXponL
Exciting news🎉
ExcellGene's scientists introduce HEKzeroT®, a #HEK293-derived line, free of SV40 T-antigen sequences, with improved growth, transfectability, and AAV virus-like particle productivity. Read all about our breakthrough in #GeneTherapy here: https://t.co/m13GCQn26N
ExcellGene SA est fière d'être #sponsor de la course annuelle féminine #LaMONTHEYSANNE ⭐️🏃♀️
Cet événement est en parfaite harmonie avec nos valeurs, car notre entreprise est fortement engagée dans la création de thérapies innovantes contre le #cancer et d'autres maladies graves.
Develop recombinant #cell lines with high productivity in 3 months! 💪 Our advanced #technologies and extensive industry #knowledge allow us to maximize efficiency and performance. Ready to connect and explore further?
Visit us at https://t.co/pgfwumSacB
#Biotech
With over 20 years of experience in supporting clients in transforming their concepts for #therapy and #vaccines, provided in the form of #DNA or #protein sequence, into successful delivery of #clinical products.
Explore our #Swiss-quality solutions at https://t.co/CdWadXpWdj
Big thanks to #BIO2023 for hosting us! Engaging with all of you and making meaningful connections was an absolute pleasure.
Reach out to us to discover our expertise in #CHO and #HEK293 cell line development by visiting https://t.co/CdWadXponL
#Biotech#CellLine#Swiss
We are at #BIO2023 in Boston, USA! 🤝
Join us at booth 1743 in the #SWISSPavilion, where we'll showcase our specialized expertise in developing and producing high-quality recombinant proteins and monoclonal antibodies, with a focus on #CHO and #HEK293 cell line development.
Join our research associate, Dr. Yoann Saucereau, as he explores our fast and dependable method to quantify #AAV particle production from transfected #HEK cells
Access this free webinar now! https://t.co/wGyJJNdWif
#GeneTherapy#OctetBLI#biotech
Let’s discover the future of biotech together at #BIO2023 😌
Connect with us at Swiss Biotech Center—Booth 1743 to explore our industry-leading #CHO & #HEK293 cell line development spanning over two decades!
#biotech#genetherapy#StandUpForScience
Happy to announce the promotion of Dr. Divor Kiseljak to COO! https://t.co/EPsQUzrljU He'll continue to expand #recombinantprotein design, gene expression & manufacturing efforts for our customers seeking #novelvaccines & protein-based #therapeutics. #ExpectGreatScience.
#BPIeurope#vienna! Want top-notch cell line development/biosimilars/lively discussions? Find our poster or Paco Pino's talk: “A CHO platform for the rapid production of vaccine antigens: From Wuhan to FrankenSpikes”. Web: https://t.co/ISzZ5aNHSJ
#BPI#biologics#bioprocessing
The threat of new troublesome variants emerging that might evade our current vaccines is real, so investing in variant-proof vaccines is a global health security imperative.
Find out more our new partnership @BharatBiotech@Sydney_Uni@ExcellGene▶️https://t.co/47xGFJffrE
🔧 Collaborating for automated cell line development: combining ExcellGene’s high-yield mammalian CHOExpress® system, together with CYTENA’s C.STATION™ next generation automated workstation, allows for unprecedented breakthroughs in cell line... https://t.co/Iw9fMRjLpH
✨ ExcellGene turns twenty! It's been an incredible journey. Florian and Maria Wurm would like to express their deepest gratitude to collaborators, colleagues, clients and partners who have trusted and supported ExcellGene over the years. https://t.co/UNmsShsCyl
"What cells do you work with?" Cell names such as CHO–K1, CHO DG 44, etc. have been in use for >40 years. But are these names still relevant in the context of today’s manufacturing activities? Read on here! https://t.co/N95ic6A7G3